Venclexta (venetoclax)

pCPA File Number: 23299

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with ibrutinib, is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Sponsor/Manufacturer:

AbbVie Corporation

CDA-AMC Project Number:

PC0402-00

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable